Skip to main content
4DMEDICAL LIMITED logo

4DMEDICAL LIMITED — Investor Relations & Filings

Ticker · 4DX ISIN · AU0000095416 LEI · 9845000A8F12A6A6FD75 ASX Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 546 across all filing types
Latest filing 2024-08-29 Annual Report
Country AU Australia
Listing ASX 4DX

About 4DMEDICAL LIMITED

https://4dmedical.com/

4DMedical Limited develops non-invasive respiratory imaging solutions centered on its proprietary XV Technology. This platform utilizes advanced algorithms to transform standard X-ray sequences into four-dimensional quantitative data, visualizing regional lung function in motion. The flagship XV Lung Ventilation Analysis Software (XV LVAS) provides clinicians with detailed maps of airflow distribution throughout the respiratory cycle, facilitating the early detection and monitoring of chronic conditions such as COPD, asthma, and interstitial lung disease. By providing objective, high-resolution insights into lung ventilation without the limitations of traditional pulmonary function tests, the company's cloud-based diagnostic tools aim to improve clinical workflows and patient management. The integration of artificial intelligence further enhances its capability to deliver precise, automated lung tissue analysis.

Recent filings

Filing Released Lang Actions
Appendix 4E - Preliminary Final Report 21 pages 430.3KB
Annual Report Classification · 95% confidence The document is titled 'Appendix 4E 4DMedical Limited' and provides detailed financial results for the year ended 30 June 2024, including consolidated statements of profit or loss, financial position, changes in equity, and cash flows. It includes comprehensive financial data, notes to the financial statements, and commentary on results. The document mentions that the financial statements are unaudited and in the process of being audited, which is typical for an annual financial report. The presence of full financial statements and detailed notes indicates this is a full annual report rather than a brief earnings release or announcement. The document is approximately 15,000 characters, which is consistent with a full report rather than a short announcement. Therefore, the document fits the definition of an Annual Report (10-K). FY 2024
2024-08-29 English
FY2024 Full year results 6 pages 624.8KB
Annual Report Classification · 95% confidence The document is titled 'FY2024 Full year results' and dated 30 August 2024. It contains detailed financial performance data for the full fiscal year ended 30 June 2024, including revenue, expenses, EBITDA, and operational highlights. The text discusses strategic acquisitions, commercial agreements, reimbursement approvals, and product development initiatives. The length is substantial (15,000 characters), and the content includes comprehensive financial and operational information typical of a full annual report. There is no indication that this is merely an announcement of a report or a certification. Therefore, this document fits the definition of an Annual Report (10-K equivalent) covering the full fiscal year and full financial performance. FY 2024
2024-08-29 English
Notification of cessation of securities - 4DX 5 pages 16.9KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the cessation (expiry) of certain options and convertible securities for 4DMedical Limited. It includes specific information about the securities that have ceased, the reasons for cessation, and the updated issued capital following these changes. The document is a formal announcement to the ASX regarding changes in the company's securities, specifically the cessation of certain securities due to expiry without exercise or conversion. This type of document is a regulatory announcement about changes in the company's capital structure, specifically cessation of securities, which aligns with the category 'Share Issue/Capital Change' (SHA). The document is not a full financial report, audit, or management report, nor is it a voting result or AGM material. It is a formal notification of capital changes related to securities cessation.
2024-08-13 English
Expiry of options and Appendix 3Y 4 pages 382.5KB
Director's Dealing Classification · 100% confidence The document is an ASX announcement regarding the expiry of employee options and changes in director's interests, specifically an Appendix 3Y (Change of Director’s Interest Notice) and Appendix 3H (Notification of cessation of securities). It details the expiry of options held by employees and the CEO, including the number of securities held before and after the change, and the nature of the change (expiry of options). This type of document is a regulatory disclosure about insider transactions and director dealings, not a financial report or earnings release. It fits the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The document length and content confirm it is not a brief announcement or a report publication notice but a detailed regulatory filing about director share transactions.
2024-08-13 English
Application for quotation of securities - 4DX 9 pages 22.5KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is a standard ASX (Australian Securities Exchange) form used for the application for quotation of securities. It details the issuance and quotation of securities under an employee incentive scheme, including the number of securities, issue date, and other listing rule requirements. This type of document is not a financial report, earnings release, or management discussion, but rather an official announcement related to the capital structure and listing of securities. Therefore, it fits the category of Share Issue/Capital Change (SHA). The document length and content confirm it is a full announcement, not just a brief notice or a report publication announcement.
2024-08-01 English
Quarterly Activity Report and Appendix 4C for Q4 FY2024 12 pages 854.6KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Activity Report and Appendix 4C for Q4 FY2024' and dated 31 July 2024. It contains detailed financial performance data for the quarter and fiscal year to date, including operating revenue, cash balances, and cash flow figures. It also provides extensive operational updates, commercial agreements, integration progress, reimbursement status, and partnership activities. The presence of substantive financial data and analysis for a quarter (Q4 FY2024) indicates this is a comprehensive interim/quarterly report rather than a brief announcement or presentation. The document length (15,000 characters) and detailed content confirm it is not merely a report publication announcement or regulatory filing. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q4 2024
2024-07-30 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.